Piper Sandler analyst David Amsellem upgraded Axsome Therapeutics to Overweight from Neutral with a price target of $90, up from $70.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXSM:
- Cantor Fitzgerald bullish on Axsome after Q2 results, Sage’s zuranolone CRL
- Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Axsome Therapeutics announces anticipated milestones
- Axsome Therapeutics reports Q2 EPS ($1.54), consensus ($1.22)
- AXSM Upcoming Earnings Report: What to Expect?